Verus Financial Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$381K Buy
330
+15
+5% +$17.7K 0.03% 98
2026
Q2
$377K Buy
315
+2
+0.6% +$2.04K 0.03% 91
2026
Q1
$283K Buy
313
+35
+13% +$35.5K 0.03% 105
2025
Q4
$295K Buy
+278
New +$266K 0.03% 99
2024
Q3
– Sell
-523
Closed -$474K – 100
2024
Q2
$474K Hold
523
– – 0.06% 50
2024
Q1
$407K Hold
523
– – 0.05% 65
2023
Q4
$335K Sell
523
-5
-0.9% -$2.92K 0.04% 72
2023
Q3
$322K Hold
528
– – 0.04% 72
2023
Q2
$242K Buy
528
+5
+1% +$2.1K 0.03% 92
2023
Q1
$224K Buy
+523
New +$176K 0.03% 91
2022
Q4
– Sell
-712
Closed -$239K – 104
2022
Q3
$239K Hold
712
– – 0.04% 89
2022
Q2
$233K Buy
+712
New +$214K 0.03% 85
2020
Q4
– Sell
-1,575
Closed -$233K – 147
2020
Q3
$233K Buy
+1,575
New +$244K 0.09% 136

Other funds holding LLY

Verus Financial Partners's LLY Position: Q3 2026 in Review

Verus Financial Partners increased its Eli Lilly (LLY) stake by 4.8% in Q3 2026, buying an estimated $17.7K and bringing the position to 330 shares worth $381K. The position accounts for 0.03% of the portfolio, ranked #98.

Verus Financial Partners first reported a position in LLY in Q3 2020 and has held it in 13 quarters since. The position peaked at $474K in Q2 2024. 4,581 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Verus Financial Partners held 330 shares of Eli Lilly worth $381K as of Q3 2026.
  • Verus Financial Partners bought 15 Eli Lilly shares in Q3 2026, an estimated $17.7K.
  • Eli Lilly made up 0.03% of Verus Financial Partners's portfolio in Q3 2026, its #98 holding.
  • Verus Financial Partners first reported a position in Eli Lilly in Q3 2020 and has held it in 13 quarters since.
  • Verus Financial Partners's Eli Lilly position peaked at $474K in Q2 2024.
  • 4,581 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Verus Financial Partners's 13F filing for Q3 2026, filed 29 Oct 2026.